StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
24
Publishing Date
2021 - 11 - 09
1
2021 - 11 - 05
1
2021 - 10 - 25
1
2021 - 10 - 21
2
2021 - 10 - 19
1
2021 - 10 - 14
1
2021 - 10 - 12
1
2021 - 10 - 06
1
2021 - 09 - 27
1
2021 - 09 - 20
1
2021 - 09 - 08
1
2021 - 09 - 07
1
2021 - 05 - 24
2
2021 - 05 - 20
2
2021 - 05 - 14
1
2021 - 05 - 13
2
2021 - 04 - 26
1
2021 - 04 - 15
1
2021 - 03 - 25
2
Sector
Health technology
17
Manufacturing
3
Professional, scientific, and technical services
3
Tags
Acquisition
51
Application
24
Awards
32
Biotech
23
Biotech-bay
23
Biotech-beach
25
Cancer
54
Ceo
29
Collaboration
36
Commercialization
31
Communication
29
Communications
27
Conference
300
Contract
26
Covid
42
Disease
24
Drug
23
Energy
61
Europe
39
Ev
30
Events
72
Expansion
38
Fda
25
Financial results
168
Food
24
Genetown
26
Growth
60
Health
44
Iot
43
Leo
21
Liver
45
Market
42
Media
36
Mobile
30
N/a
2628
Offering
56
Partnership
45
People
27
Pharm-country
21
Pharma
30
Phase 1
36
Phase 2
34
Phase 3
31
Positive
30
Presentation
55
Program
21
Research
137
Results
292
Risk
24
Sales
27
Security
29
Software
28
Spac
21
Technology
104
Test
50
Therapeutics
25
Therapy
35
Treatment
41
Trial
88
Vaccine
34
Entities
Abbvie inc.
2
Aldeyra therapeutics, inc.
1
Astria therapeutics, inc.
1
Atara biotherapeutics, inc.
1
Cassava sciences, inc.
1
Cellectar biosciences, inc.
1
Cyclo therapeutics inc - class a
2
Cymabay therapeutics inc.
1
Endo international plc
1
Gain therapeutics inc
1
Glaxosmithkline plc
1
Global blood therapeutics, inc.
1
Immunitybio inc
2
Inmune bio inc.
1
Logicbio therapeutics, inc.
1
Longeveron llc - class a
1
Lumos pharma, inc.
1
Rhythm pharmaceuticals, inc.
1
Selecta biosciences, inc.
1
Solid biosciences inc.
1
Voyager therapeutics, inc.
1
Symbols
ABBV
2
ALDX
1
ATRA
1
ATXS
1
CBAY
1
CLRB
1
CYTH
2
ENDP
1
GANX
1
GBT
1
GSK
1
IBRX
2
INMB
1
LGVN
1
LOGC
1
LUMO
1
RYTM
1
SAVA
1
SELB
1
SLDB
1
VYGR
1
Exchanges
Nasdaq
21
Nyse
3
Crawled Date
2021 - 11 - 09
1
2021 - 11 - 05
1
2021 - 10 - 25
1
2021 - 10 - 21
2
2021 - 10 - 19
1
2021 - 10 - 14
1
2021 - 10 - 12
1
2021 - 10 - 06
1
2021 - 09 - 27
1
2021 - 09 - 20
1
2021 - 09 - 08
1
2021 - 09 - 07
1
2021 - 05 - 24
2
2021 - 05 - 20
2
2021 - 05 - 14
1
2021 - 05 - 13
2
2021 - 04 - 26
1
2021 - 04 - 15
1
2021 - 03 - 25
2
Crawled Time
00:00
64
00:20
7
01:00
33
02:00
15
03:00
14
04:00
8
04:20
3
05:00
19
06:00
22
07:00
29
08:00
36
08:20
3
09:00
29
10:00
33
10:13
2
10:41
2
11:00
164
11:03
2
12:00
410
12:01
6
12:03
11
12:04
2
12:15
39
12:20
87
12:25
3
12:30
66
13:00
276
13:01
6
13:03
7
13:04
3
13:05
4
13:15
24
13:20
59
13:30
60
13:47
2
14:00
193
14:01
6
14:02
2
14:08
2
14:15
20
14:20
25
14:27
3
14:30
40
15:00
127
15:01
4
15:15
9
15:20
9
15:30
25
16:00
73
16:20
19
17:00
81
18:00
61
19:00
58
20:00
72
20:20
6
21:00
111
21:03
2
22:00
78
22:15
2
23:00
58
Source
ir.stockpr.com
1
www.biospace.com
14
www.globenewswire.com
4
www.nantkwest.com
2
www.prnewswire.com
3
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Disease
crawled time :
13:15
save search
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY Trial in Patients with Dry Eye Disease and Reiterates New Drug Application (NDA) Submission Guidance
Published:
2021-11-09
(Crawled : 13:15)
- biospace.com/
ALDX
4
|
$3.98
2.84%
2.76%
640K
|
Health Technology
|
-56.95%
|
O:
1.11%
H:
3.41%
C:
1.76%
new drug
dry eye
disease
eye
application
eye disease
drug
phase 3
trial
submission
enroll
Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer’s Disease Trial
Published:
2021-11-05
(Crawled : 13:15)
- biospace.com/
LGVN
|
News
P
6 d
|
$2.08
-41.08%
-69.71%
3.3M
|
|
-50.94%
|
O:
-3.05%
H:
0.61%
C:
-5.57%
disease
alzheimer
phase 2
research
trial
alzheimer’s
alzheimer's disease
alzheimer's
Endo Announces First-Ever XIAFLEX® (collagenase clostridium histolyticum) Television Commercial, Bent Carrot, and Branded Campaign to Raise Awareness of Peyronie's Disease
Published:
2021-10-25
(Crawled : 13:15)
- biospace.com/
ENDP
|
$0.2926
-9.6%
|
Health Technology
|
-93.65%
|
O:
0.0%
H:
3.9%
C:
2.39%
disease
LogicBio Therapeutics Announces Successful Repopulation of Diseased Livers in Mice with Healthy Corrected Hepatocytes in Two New Indications Using GeneRide™ Genome Editing Technology
Published:
2021-10-21
(Crawled : 13:15)
- biospace.com/
LOGC
|
$2.07
-0.48%
|
Health Technology
|
-49.01%
|
O:
5.2%
H:
0.0%
C:
-8.24%
disease
genome editing
technology
liver
Selecta Biosciences and Genovis Enter Exclusive License Agreement to Advance Next-Generation IgG Protease in Gene Therapy and Autoimmune Disease
Published:
2021-10-21
(Crawled : 13:15)
- biospace.com/
SELB
M
|
$0.8812
-8.0%
2.12%
0
|
Health Technology
|
-77.11%
|
O:
0.0%
H:
4.37%
C:
1.54%
disease
gene therapy
therapy
license
ImmunityBio Announces Primary Endpoint Met in a Second Indication in Bladder Cancer Trial with 57% Disease-Free Survival in Patients with BCG Unresponsive Papillary Disease
Published:
2021-10-19
(Crawled : 13:15)
- nantkwest.com
IBRX
|
$5.25
6.71%
6.29%
4.3M
|
Manufacturing
|
-41.32%
|
O:
0.9%
H:
2.89%
C:
1.78%
disease
bladder cancer
cancer
trial
bladder
Rhythm Pharmaceuticals Presents New Data on Experience of People Living with Rare Genetic Diseases of Obesity and Provides Updates on Uncovering Rare Obesity® Genetic Testing Program
Published:
2021-10-14
(Crawled : 13:15)
- biospace.com/
RYTM
A
|
$38.4
-0.31%
-0.31%
600K
|
Health Technology
|
239.96%
|
O:
1.68%
H:
8.09%
C:
0.52%
disease
obesity
genetic
test
rare
Astria Therapeutics to Present Findings on Burdens of Disease and Treatment in Hereditary Angioedema at the 2021 NORD Rare Diseases and Orphan Products Breakthrough Summit
Published:
2021-10-12
(Crawled : 13:15)
- biospace.com/
ATXS
|
$10.53
-5.14%
-5.41%
550K
|
Manufacturing
|
50.2%
|
O:
0.0%
H:
5.68%
C:
4.47%
disease
treatment
rare
hereditary angioedema
Cassava Sciences Initiates a Phase 3 Efficacy Trial of Simufilam for the Treatment of Patients with Alzheimer’s Disease
Published:
2021-10-06
(Crawled : 13:15)
- biospace.com/
SAVA
|
$21.27
1.14%
1.13%
630K
|
Health Technology
|
-62.8%
|
O:
-0.51%
H:
5.45%
C:
-7.68%
disease
alzheimer
treatment
phase 3
trial
refocus-alz
rethink-alz
alzheimer’s
alzheimer's disease
alzheimer's
European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of tab-cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (PTLD)
Published:
2021-09-27
(Crawled : 13:15)
- biospace.com/
ATRA
|
$0.7201
5.65%
5.35%
830K
|
Health Technology
|
-95.99%
|
O:
1.0%
H:
3.09%
C:
1.75%
disease
treatment
europe
positive
iot
tab-cel
cel
AbbVie Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI®) for the Treatment of Patients 16 Years and Older with Moderate to Severe Crohn's Disease
Published:
2021-09-20
(Crawled : 13:15)
- prnewswire.com
ABBV
|
$164.25
1.05%
-0.76%
4M
|
Health Technology
|
52.45%
|
O:
-1.33%
H:
1.31%
C:
0.28%
disease
treatment
fda
risankizumab
order
Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-derived iPSC Study Evaluating STAR Compounds as a Treatment for Gaucher and Parkinson’s Disease
Published:
2021-09-08
(Crawled : 13:15)
- globenewswire.com
GANX
|
$3.14
-0.63%
-0.64%
81K
|
Professional, Scientific, and T...
|
-59.75%
|
O:
19.11%
H:
3.61%
C:
0.85%
disease
treatment
positive
topline
parkinson
U.S. FDA Accepts for Priority Review Supplemental New Drug Application for Oxbryta® (voxelotor) for the Treatment of Sickle Cell Disease in Children Ages 4 to 11
Published:
2021-09-07
(Crawled : 13:15)
- biospace.com/
GBT
|
$68.49
0.02%
-0.02%
|
Health Technology
|
127.13%
|
O:
1.23%
H:
1.51%
C:
-2.39%
new drug
disease
treatment
fda
oxbryta
children
drug
fda acceptance
AbbVie Presents New Late-Breaking Data Analyses Showing Risankizumab (SKYRIZI®) Achieves Clinical Remission and Endoscopic Response at Week 12 in Patients with Moderate to Severe Crohn's Disease
Published:
2021-05-24
(Crawled : 13:15)
- prnewswire.com
ABBV
|
$164.25
1.05%
-0.76%
4M
|
Health Technology
|
41.17%
|
O:
0.4%
H:
0.19%
C:
-0.58%
disease
risankizumab
INmune Bio, Inc. to Participate in Alzheimer Disease Panel Presented by Maxim Group LLC and hosted by M-Vest on May 26th, 2021
Published:
2021-05-24
(Crawled : 13:15)
- globenewswire.com
INMB
|
$8.51
-7.0%
-7.52%
150K
|
Health Technology
|
-39.53%
|
O:
3.52%
H:
0.14%
C:
-10.88%
disease
alzheimer
alzheimer’s
alzheimer's disease
alzheimer's
ImmunityBio to Present Preliminary Phase 2 Data of 68% Durable Disease Control with Anktiva Plus Checkpoint Inhibitor in First 140 Patients Enrolled with Lung Cancer and Multiple Tumor Types Who Failed Prior Checkpoint Therapy at ASCO 2021
Published:
2021-05-20
(Crawled : 13:15)
- nantkwest.com
IBRX
|
$5.25
6.71%
6.29%
4.3M
|
Manufacturing
|
-67.17%
|
O:
0.19%
H:
9.44%
C:
6.5%
disease
phase 2
lung cancer
therapy
cancer
enroll
Cyclo Therapeutics to Participate in the M-Vest Virtual Conference Series: Alzheimer’s Disease Panel
Published:
2021-05-20
(Crawled : 13:15)
- ir.stockpr.com
CYTH
|
$1.25
2.46%
2.4%
31K
|
Professional, Scientific, and T...
|
-82.77%
|
O:
0.56%
H:
5.76%
C:
5.2%
disease
alzheimer
conference
alzheimer’s
alzheimer's disease
alzheimer's
Cellectar to Participate at the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021
Published:
2021-05-14
(Crawled : 13:15)
- globenewswire.com
CLRB
|
$3.2
-3.32%
-3.44%
840K
|
Health Technology
|
164.8%
|
O:
4.8%
H:
2.29%
C:
-1.53%
disease
rare
CymaBay Welcomes Dennis D. Kim, MD, MBA as Chief Medical OfficerExperienced Biotech Executive, Physician-Scientist and Orphan Disease Expert to Lead Clinical/Medical Functions as Seladelpar Advances in Phase 3 and as Pipeline Programs Mature
Published:
2021-05-13
(Crawled : 13:15)
- biospace.com/
CBAY
|
$32.48
0.03%
8.4M
|
Health Technology
|
656.88%
|
O:
-1.72%
H:
2.7%
C:
-2.4%
disease
biotech
phase 3
iot
Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit
Published:
2021-05-13
(Crawled : 13:15)
- globenewswire.com
LUMO
|
$2.52
3.16%
14K
|
Health Technology
|
-74.8%
|
O:
-0.1%
H:
3.96%
C:
-2.4%
disease
rare
pharma
← Previous
1
2
Next →
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
News
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
News
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.